Presenters

Associate Professor
Division of Gynecologic Oncology
Department of Obstetrics & Gynecology
David Geffen School of Medicine at UCLA

Dr__Chase_Presentation_Objectives.docx

Dr. Dana Chase graduated with honors from Brown University in 1996, and earned her medical degree at the University of California, Irvine, in 2003. She completed a residency in obstetrics and gynecology at the University of California, Irvine, in 2007 and subsequently went on to complete her fellowship in gynecologic oncology at the University of California, Irvine, in 2011. In 2011, Dr. Chase joined the Division of Gynecologic Oncology at St. Joseph’s Hospital and Medical Center in Phoenix. She is now a Gynecologic Oncologist at David Geffen School of Medicine at UCLA.  Dr. Chase an Associate Professor at the Division of Gynecologic Oncology

Department of Obstetrics & Gynecology David Geffen School of Medicine at UCLA

Dr. Chase’s expertise includes research and collaborative projects with colleagues on scientific questions related to quality of life, symptom management, and supportive care. She is a member of NRG Oncology and a member of the group’s Health Outcomes Research Committee, Patient Centered Outcomes Research Committee, Cancer Prevention and Control, Elderly Committee, and is on the group’s Data Monitoring Committee Panel A. 

Dr. Chase is a fellow of the American Congress of Obstetricians and Gynecologists, as well as an active member of the Society of Gynecologic Oncology and American Society of Clinical Oncology. She is a eviewer for Gynecologic Oncology and the American Journal of Obstetrics and Gynecology.  Dr. Chase has authored more than 61 peer-reviewed articles along with over 45 abstracts dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life.

Heather_McArthur_Presentation_Goal_and_Objectives.docx

Heather McArthur, MD, MPH is the Clinical Director of Breast Cancer at University of Texas Southwestern Medical Center (UTSW) and Komen Distinguished Chair in Clinical Breast Research. Dr. McArthur is a medical oncologist with a clinical practice dedicated to the care of patients with breast cancer. Her research activities are focused on innovations in the diagnosis and treatment of breast cancer, with a particular interest in novel immune therapy strategies. For example, she is currently evaluating the impact of tumor destruction with freezing (cryoablation) or radiation in combination with immune stimulation for the treatment of women with early stage breast cancer. It is hoped that by augmenting one's immune response to the unique biologic features of one's tumor, that an affected individual may develop long-term immunity against their tumor, and thus, be cured.

Dr. McArthur completed formal medical oncology training in Canada where she was awarded a highly competitive grant that funded an advanced fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Thereafter, she joined MSKCC as faculty where she developed the institutional breast cancer immunotherapy program before joining CSMC in 2016 and UTSW in 2021. She has a Master’s in Public Health with a focus on clinical trial design from Harvard University and has mentored many medical students, residents, fellows, and junior faculty in the conduct and reporting of several studies - two of which directly informed National Comprehensive Cancer Network treatment guidelines.

Dr. McArthur has held several leadership positions in the field including Co-Chair of a Breast International Group Immunotherapy Taskforce, member of a National Cancer Institute (NCI) Breast Cancer Immuno-Oncology (IO) Working Group, member of a NCI Breast Cancer IO Task Force, and member of an Alliance for Clinical Trials in Oncology IO Committee. She has served the American Society of Clinical Oncology (ASCO) on the Annual Meeting IO Scientific Committee, the YIA/CDA Grant Selection Committee, the Breast Cancer Symposium Program Committee, the Annual Meeting Grant Writing Workshop, a Guideline Expert Panel, and Educational Book Expert Panels. She has participated in the ASCO Leadership Development Program; reviewed manuscripts for various high impact journals; authored numerous articles; and served on many study steering committees. She has designed, conducted, and reported on many studies in breast cancer and is currently the co-PI for a large, randomized, international phase 3 study exploring adjuvant chemotherapy with or without immune therapy for the treatment of triple negative breast cancer (IMpassion030).

Teresa_Knoop_Presentation_2023.pptx

Teresa Knoop is an Assistant Director of the Clinical Trials Shared
Resource at the Vanderbilt-Ingram Cancer Center in Nashville, TN. She
graduated from Murray State University in Murray,KY with a BSN and
earned her Master’s Degree in Nursing from the Vanderbilt University
School of Nursing. Teresa is an Advanced Oncology Certified Nurse
through the Oncology Nursing Society and is a Certified Clinical Research
Professional through the Society of Clinical Research Associates. She has
published articles in nursing journals and speaks frequently on the topics
of molecularly targeted cancer therapies and cancer clinical trials

Navigating_the_Evolving_Bladder_Cancer_Landscape.pdf

Brenda_Martone_Presentation_Goals_and_Objectives_.docx

Brenda Martone is an adult nurse practitioner and certified advanced oncology nurse practitioner at Northwestern Medicine in outpatient GU oncology. I began my oncology career over 34 years ago in gyn-oncology,  then transitioned to inpatient nursing caring for both hematology and solid tumor patients at Loyola Medical Center. I earned my MSN from Loyola University and practiced as an oncology nurse specialist. I then   served in a leadership role in clinical trials at Loyola Medical Center. I continued as a CNS in clinical trials at Northwestern University in Chicago IL with a focus on GU oncology and melanoma.  

I returned to school to earn my post master's certificate as an adult nurse practitioner from Rush University in Chicago IL.  I have been an APP for over 27 years, and have spent the last 15 years as an NP in the GU oncology clinic.

I was nudged into public speaking by a very supportive Pfizer rep and began presenting on numerous speakers bureaus in renal, bladder and prostate cancer and fell in love with sharing and teaching others. Then I had this great opportunity to co-chair a program with Kathleen Burns, NP at City of Hope, and I learned how exciting and rewarding it was to develop a presentation and program. 

I have since had the opportunity and pleasure to present numerous regional and national lectures on topics related to GU malignancies. These include JADPRO LIVE 2020 Advanced prostate cancer and considerations for advanced practitioners. I was also been invited to present the APP's view on several Research to Practice with Dr Neil Love. I have been involved with UroToday and presented on the various topics including Patients' Understanding of Clinical Trials, Assessing and Managing Toxicities with Immune Checkpoint Inhibitors, Transitioning Patients to an Oral GnRH Antagonist, Optimizing Patient Outcomes,  Optimal Patient Selection for Treatment with Radium-223 in mCRPC Towards Improved Overall Survival and Improved Quality of Life, and One Patient's Perspectives About Participating in a Randomized Clinical Trial. I am a founding member of GU nurses connect and have been involved in podcasts related to prostate cancer.

Most recent opportunities include working with the CCO to provide a program regarding prostate cancer to local ONS chapters, prostate cancer presentation at the Oncology nurse summit, development of a program with PCE at Oncology Nursing Summit about PARP inhibitors and prostate cancer, lead author “Darolutamide can be effectively and safely administered in combination with androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate cancer” poster presentation at ONS Congress 2023 and being invited by Peerview and the bladder cancer advocacy network (BCAN) as chairperson for a program titled “Meeting patients’ needs through optimal nursing strategies in personalized bladder cancer care” also at ONS Congress 2023.

When I am not working:

I love to walk on the lakefront and completed 2 half marathon walks last summer.

I enjoy taking Pure Barre classes.

I love to travel and I have had the pleasure to visit 5 out of the 7 continents.

My most memorable trips are to Antarctica and last summer to Norway, Faroe Islands (artic circle) and Iceland

Dr__Page_Presentation_Goals_and_Objectives_.docx

Dr. David B. Page is a medical oncologist and clinical investigator at the Providence Cancer Institute in Portland, Oregon. His area of expertise is in the field of breast cancer immunotherapy. 

He completed a Bachelor’s of the Arts at the University of Chicago, a medical doctorate at Northwestern University, followed by internal medicine residency at Columbia University / New York Presbyterian and medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City. 

He was inspired early in his career at MSKCC when he had the privilege of working alongside mentors Jedd Wolchok and James Allison of the melanoma and immunotherapeutics department, caring for some of the first immune checkpoint therapy patients to be cured of metastatic cancer on the early phase ipilimumab clinical trials. Since then, he has devoted his career to developing immune checkpoint therapies for clinical use in breast cancer, serving as PI for a number of trials, including a phase II study evaluating locoregional cytokine therapy plus pembrolizumab in early stage TNBC, as well as a phase II study evaluating androgen receptor blockade as a mechanism of enhancing immune checkpoint response. He also has served on various immunotherapy-related committees, including the NCI Breast Immuno-oncology task force, the SITC Breast Immunotherapy expert panel, and the SITC multispectral immunofluorescence working group. 

Finally, as a life-long learner, Dr. Page has recently completed a graduate degree in biostatistics, with the aim of applying statistical regression approaches to improve prognostic and predictive performance of biomarkers such as the stromal tumor infiltrating lymphocyte score, and high-throughput assays including RNA sequencing and T-cell receptor sequencing. 

Dr__Kurtin_Presentation_Handout.pdf

Dr__Robert_Lentz_Presentation_Objectives_.docx

Dr. Robert Lentz is an Assistant Professor of Medicine/Medical Oncology at the University of Colorado Anschutz Medical Campus and Cancer Center (Aurora, CO). He received his MD from Vanderbilt University School of Medicine in Nashville, TN, completed Internship and Residency at the Northwestern University Feinberg School of Medicine in Chicago, IL, and Hematology/Oncology Fellowship at the University of Colorado. His clinical interests are in treating patients with gastrointestinal cancers within a multidisciplinary team. He is active in clinical and translational research, including leading multiple clinical trials. He is a member of the American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR), Society for Immunotherapy of Cancer (SITC), European Society for Medical Oncology (ESMO), and the Academic Gastrointestinal Cancer Consortium (AGICC).